Table 4. Univariate and multivariate Cox survival analysis in patients with BCLC stage B hepatocellular carcinoma.
| n = 503 | Crude Hazard Ratio | Adjusted Hazard Ratio | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Diabetes mellitus (no/yes) | 1.54 (1.09–2.17) | 0.014 | 1.77 (1.24–2.51) | 0.002 |
| Age (per 10 years increment) | 1.09 (0.97–1.22) | 0.157 | - | - |
| Male gender (female/male) | 0.86 (0.59–1.28) | 0.463 | - | - |
| Hepatitis B (negative/positive) | 1.00 (0.74–1.35) | 0.992 | - | - |
| Hepatitis C (negative/positive) | 0.98 (0.69–1.39) | 0.914 | - | - |
| Alcoholism (no/yes) | 1.29 (0.83–2.00) | 0.260 | - | - |
| Albumin (per 1 g/dl increment) | 1.72 (1.30–1.22) | <0.001 | 1.67 (1.27–2.22) | <0.001 |
| Bilirubin (per 1 mg/dl increment) | 1.11 (0.99–1.24) | 0.082 | 1.10 (0.97–1.25) | 0.144 |
| INR (per 1.0 increment) | 2.24 (1.00–5.02) | 0.051 | 2.36 (0.89–6.27) | 0.085 |
| Sodium (per 1 mEq/l increment) | 0.97 (0.92–1.02) | 0.207 | - | - |
| AFP (per 10,000 ng/ml increment) | 1.02 (0.97–1.07) | 0.395 | - | - |
| eGFR (per 10 mL/min/1.73 m2 increment) | 0.98 (0.92–1.05) | 0.595 | - | - |
| Variceal bleeding (no/yes) | 2.49 (0.62–10.08) | 0.200 | - | - |
| Total tumor volume (per 1,000 ml increment) | 1.29(1.01–1.64) | 0.041 | 1.51 (1.19–1.93) | 0.001 |
| Vascular invasion (no/yes) | - | - | - | - |
| Ascites (no/yes) | 1.34 (0.68–2.62) | 0.396 | - | - |
| Platelet count (per 10,000 mm3 increment) | 0.98 (0.96–1.00) | 0.099 | 0.99 (0.97–1.01) | 0.182 |
Factors with P value < 0.1 in the univariate analysis were introduced into the Cox multivariate survival analysis.
The forepart of the parentheses was set as the reference group in univariate and multivariate analysis.
AFP, alpha-fetoprotein; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; INR, international normalized ratio